These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23164505)

  • 1. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats.
    Luoni A; Hulsken S; Cazzaniga G; Racagni G; Homberg JR; Riva MA
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1319-30. PubMed ID: 23164505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex.
    Luoni A; Macchi F; Papp M; Molteni R; Riva MA
    Int J Neuropsychopharmacol; 2014 Oct; 18(4):. PubMed ID: 25522402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.
    Calabrese F; Luoni A; Guidotti G; Racagni G; Fumagalli F; Riva MA
    Psychopharmacology (Berl); 2013 Mar; 226(1):101-12. PubMed ID: 23093383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developmental influence of the serotonin transporter on the expression of npas4 and GABAergic markers: modulation by antidepressant treatment.
    Guidotti G; Calabrese F; Auletta F; Olivier J; Racagni G; Homberg J; Riva MA
    Neuropsychopharmacology; 2012 Feb; 37(3):746-58. PubMed ID: 22012473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms.
    Calabrese F; Molteni R; Cattaneo A; Macchi F; Racagni G; Gennarelli M; Ellenbroek BA; Riva MA
    Mol Pharmacol; 2010 May; 77(5):846-53. PubMed ID: 20159945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment.
    Luoni A; Rocha FF; Riva MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():94-101. PubMed ID: 24361635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress.
    Fumagalli F; Calabrese F; Luoni A; Bolis F; Racagni G; Riva MA
    Int J Neuropsychopharmacol; 2012 Mar; 15(2):235-46. PubMed ID: 21349227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the development of lurasidone as a treatment for patients with acute schizophrenia.
    Yasui-Furukori N
    Drug Des Devel Ther; 2012; 6():107-15. PubMed ID: 22675261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence.
    Luoni A; Berry A; Calabrese F; Capoccia S; Bellisario V; Gass P; Cirulli F; Riva MA
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):986-95. PubMed ID: 24440552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of serotonin transporter alters BDNF expression in the rat brain during early postnatal development.
    Calabrese F; Guidotti G; Middelman A; Racagni G; Homberg J; Riva MA
    Mol Neurobiol; 2013 Aug; 48(1):244-56. PubMed ID: 23564488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stress Modifies the Expression of Glucocorticoid-Responsive Genes by Acting at Epigenetic Levels in the Rat Prefrontal Cortex: Modulatory Activity of Lurasidone.
    Brivio P; Sbrini G; Tarantini L; Parravicini C; Gruca P; Lason M; Litwa E; Favero C; Riva MA; Eberini I; Papp M; Bollati V; Calabrese F
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of lurasidone in behavioral models of depression. Role of the 5-HT₇ receptor subtype.
    Cates LN; Roberts AJ; Huitron-Resendiz S; Hedlund PB
    Neuropharmacology; 2013 Jul; 70():211-7. PubMed ID: 23416039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered expression and modulation of activity-regulated cytoskeletal associated protein (Arc) in serotonin transporter knockout rats.
    Molteni R; Calabrese F; Maj PF; Olivier JD; Racagni G; Ellenbroek BA; Riva MA
    Eur Neuropsychopharmacol; 2009 Dec; 19(12):898-904. PubMed ID: 19576731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment.
    Calabrese F; Savino E; Papp M; Molteni R; Riva MA
    Pharmacol Res; 2016 Feb; 104():140-50. PubMed ID: 26742719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.
    Tarazi FI; Riva MA
    Expert Opin Drug Discov; 2013 Oct; 8(10):1297-307. PubMed ID: 23837554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux.
    Huang M; Horiguchi M; Felix AR; Meltzer HY
    Neuroreport; 2012 May; 23(7):436-40. PubMed ID: 22415605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.
    Yuen EY; Li X; Wei J; Horiguchi M; Meltzer HY; Yan Z
    Mol Pharmacol; 2012 Feb; 81(2):113-9. PubMed ID: 22072817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential use of lurasidone for the treatment of bipolar psychosis.
    Carta MG; Moro MF; Nardi AE; Calabrese JR
    Expert Opin Investig Drugs; 2015 Apr; 24(4):575-84. PubMed ID: 25633339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone: a new treatment option for schizophrenia.
    Owen RT
    Drugs Today (Barc); 2011 Nov; 47(11):807-16. PubMed ID: 22146224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.